About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Financial calendar

Upcoming events

2026
2025
2024
2023
2022
2021
2020
2019
All years

Financial

Events
Financial

August 12, 2025

Interim report Q2 2025

Read more

November 11, 2025

Interim report Q3 2025

Read more

February 12, 2026

Interim report Q4 2025

Read more

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com